In the open access journal chemotherapy dr Keppel Hesselink published an important commentary on the use of PEA in chemotherapy.
He pointed out that dose limiting side effects in chemotherapy are a crux medicorum. Targeted cytoprotection such as protection against neurotoxicity and ototoxicity is much sought after. He discussed the data published In 2011 by the group of Professor Cruccu of the University of Rome. This group published the results of a clinical trial in 20 patients, showing that the natural compound Palmitoylethanolanide (PEA) administered concomitantly to thalidomide and bortezomib could reduce neuropathic pain after chemotherapy and restore the disturbed neurophysiology of nerves. These results support the notion of targeted cytoprotection during chemotherapy. This compound therefore could play a valuable role in the field of cancer treatment.
The results of the data he discssed has great value for oncologists; PEA may not only reduce polyneuropathic damage during and after chemotherapy, it may also enable oncologists to dose higher or longer in critical situations, and enhance the efficacy and safety of chemotherapy. Furthermore it reduces neuropathic pain after a chemotherapeutic regime.